Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Debt (2021 - 2025)

Historic Total Debt for Verrica Pharmaceuticals (VRCA) over the last 4 years, with Q3 2025 value amounting to $12.5 million.

  • Verrica Pharmaceuticals' Total Debt changed N/A to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is N/A changed from last year.
  • Verrica Pharmaceuticals' Total Debt amounted to $12.5 million in Q3 2025.
  • Verrica Pharmaceuticals' 5-year Total Debt high stood at $42.3 million for Q2 2022, and its period low was $12.5 million during Q3 2025.
  • In the last 4 years, Verrica Pharmaceuticals' Total Debt had a median value of $40.8 million in 2021 and averaged $30.0 million.
  • The largest annual percentage gain for Verrica Pharmaceuticals' Total Debt in the last 5 years was 327.03% (2022), contrasted with its biggest fall of 314.11% (2022).
  • Over the past 4 years, Verrica Pharmaceuticals' Total Debt (Quarter) stood at $41.7 million in 2021, then rose by 1.44% to $42.3 million in 2022, then tumbled by 69.41% to $12.9 million in 2024, then fell by 3.71% to $12.5 million in 2025.
  • Its Total Debt stands at $12.5 million for Q3 2025, versus $12.7 million for Q2 2025 and $12.8 million for Q1 2025.